Table 3. Correlations between change from baseline in efficacy of 300 µg/d transdermal testosterone.
PFSF: Profile of female sexual function; PDS: Personal distress scale; SAL: Sexual activity log; CI: Confidence interval
| Study | Evaluation tools | Mean of change from baseline after 24 weeks [95% CI] | p-value |
| Dose: 300 µg/d | |||
| Braunstein G. et al. [1] | PFSF scores - Sexual desire | 5.3 [no CI] | 0.05 |
| PDS score | - | 0.13 | |
| SAL score - No. of satisfying episodes | 8.06 [no CI] | <0.05 | |
| Davis S. et al. [2] | PFSF scores - Sexual desire | 7 [no CI] | <0.001 |
| PDS score | -11 [no CI] | <0.001 | |
| SAL score - No. of satisfying episodes | 2.1 [no CI] | <0.001 | |
| Panay N. et al. [3] | PFSF scores - Sexual desire | 7.5 [no CI] | <0.005 |
| PDS score | -11.52 [-14.58 to -8.46] | 0.0024 | |
| SAL score - No. of satisfying episodes | 1.16 [0.82-1.5] | 0.0089 | |
| Shifren J. et al. [4] | PFSF scores - Sexual desire | 5.79 [2.82-8.76] | 0.0001 |
| PDS score | -9.04 [-13.49 to -4.58] | 0.0001 | |
| SAL score - No. of satisfying episodes | 1.38 [0.72-2.03] | <0.0001 | |
| Simon J. et al. [5] | PFSF scores - Sexual desire | 5.12 [2.20-8.04] | 0.0006 |
| PDS score | -7.70 [-12.14 to -3.26] | 0.0006 | |
| SAL score - No. of satisfying episodes | 1.11 [0.5-1.73] | 0.0003 |